[go: up one dir, main page]

CY1123589T1 - Αντισωματα που δεσμευουν την il-23 - Google Patents

Αντισωματα που δεσμευουν την il-23

Info

Publication number
CY1123589T1
CY1123589T1 CY20201101081T CY201101081T CY1123589T1 CY 1123589 T1 CY1123589 T1 CY 1123589T1 CY 20201101081 T CY20201101081 T CY 20201101081T CY 201101081 T CY201101081 T CY 201101081T CY 1123589 T1 CY1123589 T1 CY 1123589T1
Authority
CY
Cyprus
Prior art keywords
antibody
useful
antibodies
bind
treating
Prior art date
Application number
CY20201101081T
Other languages
English (en)
Inventor
Catherine Brautigam Beidler
Stuart Willis Bright
Daniel Scott GIRARD
Kristine Kay Kikly
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1123589T1 publication Critical patent/CY1123589T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει αντίσωμα που δεσμεύεται στην υπομονάδα pi 9 της IL-23 ανθρώπου και χαρακτηρίζεται από το ότι διαθέτει υψηλή συγγένεια, εκλεκτικότητα και εξουδετερωτικές ιδιότητες. Το αντίσωμα είναι χρήσιμο στην αντιμετώπιση ή την πρόληψη μιας αυτοάνοσης ή φλεγμονώδους πάθησης που επιλέγεται από την ομάδα που αποτελείται από πολλαπλή σκλήρυνση, ρευματοειδή αρθρίτιδα, ψωρίαση, φλεγμονώδεις νόσους του εντέρου, αγκυλοποιητική σπονδυλίτιδα, νόσο μοσχεύματος εναντίον ξενιστή, λύκο και μεταβολικό σύνδρομο. Το αντίσωμα είναι επίσης χρήσιμο στην αντιμετώπιση του καρκίνου.
CY20201101081T 2013-03-08 2020-11-16 Αντισωματα που δεσμευουν την il-23 CY1123589T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361774732P 2013-03-08 2013-03-08
PCT/US2014/020064 WO2014137962A1 (en) 2013-03-08 2014-03-04 Antibodies that bind il-23

Publications (1)

Publication Number Publication Date
CY1123589T1 true CY1123589T1 (el) 2022-03-24

Family

ID=51488096

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20201101081T CY1123589T1 (el) 2013-03-08 2020-11-16 Αντισωματα που δεσμευουν την il-23
CY2023021C CY2023021I2 (el) 2013-03-08 2023-10-06 Αντισωματα που δεσμευουν την il-23

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2023021C CY2023021I2 (el) 2013-03-08 2023-10-06 Αντισωματα που δεσμευουν την il-23

Country Status (41)

Country Link
US (3) US9023358B2 (el)
EP (3) EP2964258B1 (el)
JP (1) JP6096938B2 (el)
KR (2) KR101775115B1 (el)
CN (1) CN105307681B (el)
AP (1) AP2015008708A0 (el)
AR (1) AR094877A1 (el)
AU (1) AU2014226094C1 (el)
BR (1) BR112015019611B1 (el)
CA (1) CA2901462C (el)
CL (1) CL2015002388A1 (el)
CY (2) CY1123589T1 (el)
DK (1) DK2964258T3 (el)
EA (1) EA031524B1 (el)
EC (1) ECSP15038626A (el)
ES (1) ES2822662T3 (el)
FI (1) FIC20230030I1 (el)
FR (1) FR23C1036I2 (el)
HK (1) HK1212252A1 (el)
HR (1) HRP20201633T1 (el)
HU (2) HUE051357T2 (el)
IL (2) IL240731B (el)
JO (1) JOP20140049B1 (el)
LT (1) LT2964258T (el)
MA (1) MA38382A1 (el)
MX (1) MX370396B (el)
MY (1) MY171226A (el)
NL (1) NL301247I2 (el)
NO (1) NO2023037I1 (el)
PE (1) PE20151529A1 (el)
PH (1) PH12015501994B1 (el)
PL (1) PL2964258T3 (el)
PT (1) PT2964258T (el)
RS (1) RS60928B1 (el)
SG (1) SG11201507176VA (el)
SI (1) SI2964258T1 (el)
TN (1) TN2015000348A1 (el)
TW (1) TWI636063B (el)
UA (1) UA123198C2 (el)
WO (1) WO2014137962A1 (el)
ZA (1) ZA201505285B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
CN108135983A (zh) * 2015-10-30 2018-06-08 伊莱利利公司 抗cgrp /抗il-23双特异性抗体及其用途
TW201902926A (zh) 2017-05-03 2019-01-16 美商美國禮來大藥廠 抗cgrp／抗il-23雙特異性抗體及其用途
TWI837532B (zh) 2018-03-30 2024-04-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
TWI725532B (zh) 2018-09-11 2021-04-21 美商美國禮來大藥廠 治療牛皮癬之方法
TWI850365B (zh) 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
MX2022004311A (es) 2019-10-15 2022-05-10 Lilly Co Eli Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
KR20220143005A (ko) 2019-12-20 2022-10-24 노바록 바이오테라퓨틱스 리미티드 항-인터루킨-23 p19 항체 및 이의 사용 방법
CN111718414B (zh) * 2020-06-12 2021-03-02 江苏荃信生物医药有限公司 抗人白介素23单克隆抗体及其应用
WO2022041390A1 (zh) * 2020-08-28 2022-03-03 江苏荃信生物医药股份有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法
TW202428304A (zh) 2020-09-10 2024-07-16 美商美國禮來大藥廠 治療性抗體調配物
US20240254217A1 (en) 2021-05-28 2024-08-01 Eli Lilly And Company Anti -il-23p19 antibody regulation of genes involved in ulcerative colitis
CN113698480B (zh) * 2021-09-18 2022-07-01 东大生物技术(苏州)有限公司 一组il-23单克隆抗体及其医药用途
EP4409298A1 (en) 2021-09-30 2024-08-07 Eli Lilly and Company Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
WO2024077113A1 (en) 2022-10-06 2024-04-11 Eli Lilly And Company Methods of treating fatigue in ulcerative colitis
WO2024178157A1 (en) 2023-02-22 2024-08-29 Eli Lilly And Company Regulation of genes in ulcerative colitis and the uses thereof
WO2024191771A1 (en) 2023-03-10 2024-09-19 Eli Lilly And Company Methods of treating ulcerative colitis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
CA2518262C (en) 2003-03-10 2014-05-06 Schering Corporation Uses of il-23 agonists and antagonists; related reagents
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
CN101252951B (zh) * 2005-06-30 2011-12-21 森托科尔公司 抗il-23抗体、组合物、方法和用途
CN101248088A (zh) * 2005-08-25 2008-08-20 伊莱利利公司 抗il-23抗体
ES2347690T3 (es) * 2005-08-25 2010-11-03 Eli Lilly And Company Anticuerpos anti-il-23.
CA2620802A1 (en) * 2005-08-31 2007-03-08 Schering Corporation Engineered anti-il-23 antibodies
ES2517420T3 (es) * 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
PL2059534T3 (pl) 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
US20100111966A1 (en) * 2007-02-23 2010-05-06 Schering Corporation Engineered anti-il-23p19 antibodies
WO2008115732A2 (en) 2007-03-20 2008-09-25 Eli Lilly And Company Anti-sclerostin antibodies
JP5290276B2 (ja) * 2007-05-08 2013-09-18 ジェネンテック， インコーポレイテッド システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2435480A1 (en) * 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
PE20141162A1 (es) * 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
KR101992502B1 (ko) * 2011-05-12 2019-06-24 제넨테크, 인크. 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법

Also Published As

Publication number Publication date
EP2964258A1 (en) 2016-01-13
CL2015002388A1 (es) 2016-03-04
CA2901462C (en) 2017-07-25
AU2014226094C1 (en) 2024-10-24
BR112015019611B1 (pt) 2023-05-02
JOP20140049B1 (ar) 2021-08-17
US9023358B2 (en) 2015-05-05
BR112015019611A2 (pt) 2017-08-22
CN105307681A (zh) 2016-02-03
PE20151529A1 (es) 2015-10-28
EP2964258B1 (en) 2020-09-02
WO2014137962A1 (en) 2014-09-12
AU2014226094A1 (en) 2015-08-27
CY2023021I1 (el) 2024-02-16
JP6096938B2 (ja) 2017-03-15
MX2015011959A (es) 2016-04-07
SG11201507176VA (en) 2015-10-29
NZ711147A (en) 2021-03-26
DK2964258T3 (da) 2020-09-14
PH12015501994A1 (en) 2016-01-11
EA031524B1 (ru) 2019-01-31
EP4311558A3 (en) 2024-04-10
MA38382A1 (fr) 2017-11-30
TN2015000348A1 (en) 2017-01-03
ZA201505285B (en) 2017-11-29
US20140255422A1 (en) 2014-09-11
TWI636063B (zh) 2018-09-21
MY171226A (en) 2019-10-03
PT2964258T (pt) 2020-11-06
KR20150113202A (ko) 2015-10-07
NL301247I1 (nl) 2023-10-11
RS60928B1 (sr) 2020-11-30
EP2964258A4 (en) 2016-10-12
IL272042B (en) 2021-07-29
JP2016510744A (ja) 2016-04-11
CA2901462A1 (en) 2014-09-12
NL301247I2 (nl) 2023-11-01
FR23C1036I2 (fr) 2024-10-04
KR101775115B1 (ko) 2017-09-05
IL240731A0 (en) 2015-10-29
HRP20201633T1 (hr) 2020-12-25
FR23C1036I1 (fr) 2023-12-08
AP2015008708A0 (en) 2015-09-30
US9688753B2 (en) 2017-06-27
PL2964258T3 (pl) 2021-02-08
TW201520225A (zh) 2015-06-01
FIC20230030I1 (fi) 2023-10-03
HK1212252A1 (en) 2016-06-10
IL272042A (en) 2020-02-27
US20170275356A1 (en) 2017-09-28
EP4311558A2 (en) 2024-01-31
LT2964258T (lt) 2020-10-12
EA201591368A1 (ru) 2015-12-30
US20150232552A1 (en) 2015-08-20
PH12015501994B1 (en) 2023-03-01
SI2964258T1 (sl) 2020-10-30
HUS2300036I1 (hu) 2024-07-28
ECSP15038626A (es) 2015-11-30
NO2023037I1 (no) 2023-10-04
UA123198C2 (uk) 2021-03-03
EP3789037A1 (en) 2021-03-10
AU2014226094B2 (en) 2016-06-23
ES2822662T3 (es) 2021-05-04
IL240731B (en) 2020-01-30
AR094877A1 (es) 2015-09-02
HUE051357T2 (hu) 2021-03-01
KR20170103037A (ko) 2017-09-12
CY2023021I2 (el) 2024-09-20
CN105307681B (zh) 2018-06-26
MX370396B (es) 2019-12-11

Similar Documents

Publication Publication Date Title
CY1123589T1 (el) Αντισωματα που δεσμευουν την il-23
SA522431756B1 (ar) Tigit أجسام مضادة لـ
CY1123493T1 (el) Παραγων συνδεσης il-17a και χρησεις αυτου
EA202091540A1 (ru) Антитела к lilrb2
CY1124619T1 (el) Αντισωματα αντι-προ/λανθανουσας μυοστατινης και χρησεις αυτων
EA201690325A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ
EA201591716A1 (ru) Антитела анти-il-33 и их применение
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
UA120981C2 (uk) Антитіло, що зв'язується з il-8, та його застосування
EA201591478A1 (ru) Биспецифические антитела против фно и ил-17
UA117575C2 (uk) Антитіло, яке специфічно зв'язується з il-17a та його застосування
EA201491622A1 (ru) Биспецифические антитела против baff и ил-17
CY1120459T1 (el) Αντισωματα των χημειοκινων παν-elr+ cxc
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
MA44061A (fr) Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
EA201892440A1 (ru) Антитела к tl1a и их применения
EA201992460A1 (ru) Антитела-агонисты btla и их применение
EA201991552A1 (ru) Анти-il-5 антитела
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
EA201891594A1 (ru) Антитела к il-17c
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
JP2017532332A5 (el)
TH180920A (th) แอนติบอดีซึ่งจับเกะากับ fcrn สำหรับการรักษาโรคภูมิต้านตนเอง
TH1401006266A (th) แอนติ-baff-แอนติ-il-17ไบสเปซิฟิกแอนติบอดี